HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Recent Breakthroughs in the Treatment of Alzheimer Disease

Experts in the diagnosis and treatment of Alzheimer disease discuss the recent approval of aducanumab, its implications on the field, and other promising therapies and diagnostic technologies in development.

EP. 1: FDA Approval of Aducanumab for Treatment of Alzheimer Disease

June 15th 2021

Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.

EP. 2: EMBARK Phase III Clinical Trial of Aducanumab in Alzheimer Disease

June 15th 2021

The importance of the ongoing EMBARK phase III clinical trial and the collection of real-world data on the use of aducanumab is discussed.

EP. 3: Identifying the Appropriate Patient for Treatment with Aducanumab in Alzheimer Disease

June 15th 2021

The challenges of identifying the appropriate patient, earlier in the disease course, for treatment with aducanumab for Alzheimer disease.

EP. 4: Impact of the Approval of Aducanumab on the Treatment Landscape in Alzheimer Disease

June 15th 2021

Impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.

EP. 5: Blood-Based Biomarkers for Diagnosis of Alzheimer Disease

June 15th 2021

The use of blood-based biomarkers for diagnosis of Alzheimer disease in the context of the comprehensive diagnosis. 

EP. 6: Future of Treating Alzheimer Disease

June 15th 2021

Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.